AngioDynamics, Inc. ANGO
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -6.62%
- 1 year
- -1.24%
- Open
- 12.32
- Prev close
- 12.35
- Mkt cap
- 504.23M
- Vol
- 475.83K
- Avg vol
- 643.04K
- EPS
- -0.78
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.89
- High
- 12.34
- Forward P/E
- -36.21
- Beta
- 0.67
- Short ratio
- 2.88
- Inst. own
- 81.31%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 8, 2025
- 50-d avg
- 7.35
- 200-d avg
- 6.77
- 1y target
- 13.00
News
-
1 week ago benzinga.com
AngioDynamics Reports DIRECT Study Findings Showing Longer Overall Survival In Stage III Pancreatic Ductal Adenocarcinoma, Gets Category I CPT Code For Open IRE Ablation Of Pancreatic Tumors, Effective January 1, 2027
Prospective, multicenter FDA IDE study found an IRE-based treatment strategy was associated with longer overall survival in Stage III pancreatic cancer; new Category I CPT code for open pancreatic…
1 week ago businesswire.com
AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system,…
2 weeks ago seekingalpha.com
AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist
AngioDynamics, Inc. remains a volatile small-cap med-tech, with promising growth drivers but inconsistent execution and margin trajectory. ANGO's AlphaVac, Auryon, and NanoKnife are gaining traction,…
2 weeks ago gurufocus.com
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular syste
2 weeks ago businesswire.com
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system,…
-
2 weeks ago benzinga.com
HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18
HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $19 to $18.
3 weeks ago zacks.com
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
3 weeks ago benzinga.com
AngioDynamics Stock Is Falling Thursday: What's Going On?
AngioDynamics Inc. (NASDAQ:ANGO) stock plunged more than 21% Thursday despite reporting better-than-expected first-quarter financial results.
3 weeks ago benzinga.com
AngioDynamics Stock Is Falling Thursday: What's Going On?
ANGO stock drops 21% as AngioDynamics reports Q1 results, names Eric Honroth as new CEO, and reaffirms FY27 guidance.
3 weeks ago benzinga.com
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo beat estimates but cut FY26 outlook; oil jumped 5%.
3 weeks ago seekingalpha.com
AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
3 weeks ago fool.com
Why AngioDynamics Crashed Today
AngioDynamics beat on both top and bottom lines this morning. The company still lost $0.04 per share, pro forma, and its GAAP loss was four times bigger.
3 weeks ago marketbeat.com
AngioDynamics Q1 Earnings Call Highlights
AngioDynamics NASDAQ: ANGO reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year…
3 weeks ago benzinga.com
AngioDynamics Q1 2027 Earnings Call: Complete Transcript
AngioDynamics (NASDAQ:ANGO) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to…
3 weeks ago zacks.com
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.
3 weeks ago defenseworld.net
AngioDynamics (NASDAQ:ANGO) Announces FY 2027 Earnings Guidance
AngioDynamics (NASDAQ: ANGO - Get Free Report) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share guidance of -0.290-0.240 for the period, compared to the…
3 weeks ago benzinga.com
Earnings Scheduled For October 8, 2026
Companies Reporting Before The Bell • Tilray Brands (NASDAQ:TLRY) is likely to report quarterly loss at $0.15 per share on revenue of $266.42 million. • Helen Of Troy (NASDAQ:HELE) is projected to…
-
3 weeks ago benzinga.com
AngioDynamics Appoints Eric Honroth As President And CEO, Effective November 2
Mr. Honroth will succeed Jim Clemmer, who will depart the Board on November 2, 2026, and will remain in a consulting capacity to ensure a smooth transition.The appointment follows a Board-led search…
-
3 weeks ago benzinga.com
AngioDynamics Affirms FY2027 Adj EPS Guidance of $(0.29)-$(0.24) vs $(0.27) Est; Affirms FY2027 Sales Guidance of $336.000M-$341.000M vs $337.400M Est
AngioDynamics (NASDAQ:ANGO) affirms FY2027 Adj EPS guidance from $(0.29)-$(0.24) to $(0.29)-$(0.24) vs $(0.27) analyst estimate. Affirms FY2027 sales outlook from $336.000 million-$341.000 million to…
-
3 weeks ago benzinga.com
AngioDynamics Q1 Adj. EPS $(0.04) Beats $(0.11) Estimate, Sales $80.915M Beat $80.500M Estimate
AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.11) by 63.64 percent. This is a 60 percent increase over losses of $(0.10)…
3 weeks ago businesswire.com
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system,…
3 weeks ago businesswire.com
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system,…
4 weeks ago businesswire.com
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment…
1 month ago businesswire.com
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment…
1 month ago defenseworld.net
32,900 Shares in AngioDynamics, Inc. $ANGO Acquired by Canada Pension Plan Investment Board
Canada Pension Plan Investment Board purchased a new position in shares of AngioDynamics, Inc. (NASDAQ: ANGO) during the undefined quarter, according to the company in its most recent disclosure with…
2 months ago defenseworld.net
AngioDynamics, Inc. $ANGO Shares Purchased by Bank of America Corp DE
Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 262.7% during the undefined quarter, according to the company in its most recent 13F filing with the…
2 months ago zacks.com
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…
2 months ago marketbeat.com
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and…
2 months ago zacks.com
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19
HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from $16 to $19.
-
3 months ago benzinga.com
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20
Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from $16 to $20.
3 months ago benzinga.com
Full Transcript: AngioDynamics Q4 2026 Earnings Call
AngioDynamics (NASDAQ:ANGO) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For…
-
3 months ago benzinga.com
Earnings Scheduled For July 14, 2026
Companies Reporting Before The Bell • Grupo Aeroportuario del (NYSE:PAC) is likely to report quarterly earnings at $3.25 per share on revenue of $862.92 million. • JPMorgan Chase (NYSE:JPM) is…
-
3 months ago benzinga.com
AngioDynamics Sees FY2027 Adj EPS $(0.29)-$(0.24) vs $(0.16) Est; Sees Sales $336.000M-$341.000M vs $329.600M Est
AngioDynamics (NASDAQ:ANGO) is looking for FY2027 Adj EPS of $(0.29)-$(0.24) vs $(0.16) analyst estimate. sees sales of $336.000 million-$341.000 million vs $329.600 million analyst estimate.
-
3 months ago benzinga.com
AngioDynamics Q4 Adj. EPS $(0.07) Beats $(0.09) Estimate, Sales $86.607M Beat $80.400M Estimate
AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 133.33 percent decrease over losses of…
-
4 months ago benzinga.com
AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment Option For Men With Benign Prostatic Hyperplasia
AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality…
5 months ago benzinga.com
Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session
U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock jumped 11.73%.
-
5 months ago benzinga.com
AngioDynamics Announces 2-Yr Results From PRESERVE Pivotal Trial Demonstrating Durable Oncologic Control And Sustained Safety Profile For NanoKnife System In Focal Ablation Of Intermediate-Risk Prostate Cancer
Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 monthsResults Presented at AUA 2026AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring…
-
6 months ago benzinga.com
Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16
Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $16.
-
-
7 months ago benzinga.com
AngioDynamics Raises FY2026 Adj EPS Guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) vs $(0.29) Est; Raises FY2026 Sales Guidance from $312.000M-$314.000M to $313.500M-$315.500M vs $312.881M Est
AngioDynamics (NASDAQ:ANGO) raises FY2026 Adj EPS guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) vs $(0.29) analyst estimate. Raises FY2026 sales outlook from $312.000 million-$314.000 million to…
-
7 months ago benzinga.com
AngioDynamics Q3 Adj. EPS $(0.07) Beats $(0.11) Estimate, Sales $78.423M Beat $76.767M Estimate
AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by 36.36 percent. This is a 12.5 percent increase over losses of…
7 months ago benzinga.com
Nasdaq Gains Over 1% On War De-Escalation Hopes: Investor Fear Eases, But Fear & Greed Index Remains In 'Extreme Fear' Zone
Stocks end higher, Fear & Greed Index eases, Trump suggests quick military withdrawal from Iran, earnings disappoint for RH and Nike.
7 months ago benzinga.com
Acuity, Lindsay And 3 Stocks To Watch Heading Into Thursday
U.S. stock futures trading lower, Acuity and Visionary Holdings report strong earnings, Lindsay Corp expected to post earnings, Globalstar shares jump after Amazon acquisition talks, AngioDynamics…
9 months ago benzinga.com
Dow Jumps Over 400 Points; US Services Activity Falls In December
Dow Jumps Over 400 Points; US Services Activity Falls In December
9 months ago benzinga.com
US Stocks Mixed; Nasdaq Gains Over 50 Points
US Stocks Mixed; Nasdaq Gains Over 50 Points
1 year ago benzinga.com
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results
1 year ago benzinga.com
Stock Market Today: Dow Futures Slip, S&P 500 Rises Amid Mixed Trade—Berkshire, Occidental, Fermi In Focus
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed.